Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Immune checkpoint inhibitors (ICIs) like CTLA-4, PD-1, and PD-L1 blockade enhance anti-tumor immunity.
• Non-antigen-specific T-cell activation by ICIs can lead to autoimmune adverse events (irAEs).
• While rash, colitis, and endocrinopathies are common irAEs, hematologic irAEs are rare but significant.

Purpose of the Study:

• To review the spectrum and understanding of rare hematologic immune-related adverse events (irAEs) associated with immune checkpoint inhibitors.
• To highlight the challenges in recognizing and managing these uncommon hematologic toxicities.

Main Methods:

• Literature review and synthesis of existing data on hematologic irAEs.
• Analysis of reported cases concerning the timing, presentation, and affected cell lines.

Main Results:

• Hematologic irAEs are rare but can impact red blood cells (e.g., autoimmune hemolytic anemia), white blood cells, and platelets (e.g., immune thrombocytopenia).
• While typically affecting a single cell line, multiple cell lines can be involved.
• Other hematologic changes like cryoglobulinemia and cytokine release syndrome can occur.
• The timing, spectrum, and clinical presentation of these events are often poorly understood due to their rarity.

Conclusions:

• Hematologic irAEs represent a rare but critical toxicity of immune checkpoint inhibitors.
• Management often involves corticosteroids, but other agents (e.g., IVIG, rituximab) or procedures may be necessary.
• Increased awareness and understanding are needed for timely diagnosis and effective treatment of these events.